Name
Jiaxing Huahe Pharmaceutical Co., Ltd.
What We Do
Huahe Pharma is an integrated radiopharmaceutical CRO and CDMO based in China, providing end-to-end support from radiolabeling to preclinical imaging and early clinical translation. Our platform combines isotope supply, radiochemistry, analytical development, animal studies and quantitative imaging under one roof.
We operate in-house PET/CT and SPECT/CT systems with a dedicated animal facility for preclinical biodistribution, kinetic modeling and dosimetry studies. Our workflow includes radiolabeling of small molecules, peptides and biomolecules, stability testing, and standardized biodistribution and image-based dosimetry analysis.
Huahe Pharma is also a licensed isotope agent of Qinshan Nuclear Power Plant, supplying Lu-177 (n.c.a.), C-14 labeled compounds, and Mo-99/Tc-99m generators (expected Q4 2026). This integrated supply chain enables seamless support for discovery, IND-enabling studies and multicenter clinical imaging projects.
Huahe Pharma is also expanding its capabilities in alpha-emitting isotopes.
Clinical-grade Ac-225 is available through our international partnerships, enabling support for radiolabeling development, preclinical evaluation, and early translational studies for targeted alpha therapy programs.
With strong collaborations across major nuclear medicine hospitals in China, we can efficiently advance tracers from preclinical confirmation to investigator-initiated clinical imaging within 6–8 months. Whether you are developing diagnostics, therapeutic radiopharmaceuticals, or evaluating new isotopes, Huahe provides comprehensive, flexible solutions
We operate in-house PET/CT and SPECT/CT systems with a dedicated animal facility for preclinical biodistribution, kinetic modeling and dosimetry studies. Our workflow includes radiolabeling of small molecules, peptides and biomolecules, stability testing, and standardized biodistribution and image-based dosimetry analysis.
Huahe Pharma is also a licensed isotope agent of Qinshan Nuclear Power Plant, supplying Lu-177 (n.c.a.), C-14 labeled compounds, and Mo-99/Tc-99m generators (expected Q4 2026). This integrated supply chain enables seamless support for discovery, IND-enabling studies and multicenter clinical imaging projects.
Huahe Pharma is also expanding its capabilities in alpha-emitting isotopes.
Clinical-grade Ac-225 is available through our international partnerships, enabling support for radiolabeling development, preclinical evaluation, and early translational studies for targeted alpha therapy programs.
With strong collaborations across major nuclear medicine hospitals in China, we can efficiently advance tracers from preclinical confirmation to investigator-initiated clinical imaging within 6–8 months. Whether you are developing diagnostics, therapeutic radiopharmaceuticals, or evaluating new isotopes, Huahe provides comprehensive, flexible solutions
Website
Categories
PET, PET/CT, Pharmaceuticals, Radioisotopes, Radiopharmaceuticals, Services, Small Animal Imaging, SPECT, SPECT/CT
Address
No. 5 Factory Building, Phase I, Isotope Industrial Park,
Haiyan County, Jiaxing City, Zhejiang Province 314300
China
Haiyan County, Jiaxing City, Zhejiang Province 314300
China